Giudici F, De Paoli A, Toffolutti F, Guzzinati S, Francisci S, Bucchi L, Gatta G, Demuru E, Mallone S, Cin AD, Caldarella A, Cuccaro F, Migliore E, Gambino ML, Ravaioli A, Puppo A, Ferrante M, Carrozzi G, Stracci F, Musolino A, Gasparotti C, Cavallo R, Mazzucco W, Vitale MF, Cascone G, Ballotari P, Ferretti S, Mangone L, Rizzello RV, Sampietro G, Mian M, Boschetti L, Galasso R, Bella F, Piras D, Sessa A, Seghini P, Fanetti AC, Pinna P, De Angelis R, Serraino D, Maso LD, Working Group A.
Am J Epidemiol. 2024 Apr 15:kwae044. doi: 10.1093/aje/kwae044. Online ahead of print.
Abstract
This study aims to estimate long-term survival, cancer prevalence, and several cure indicators for Italian women with gynaecological cancers. Thirty-one cancer registries, representing 47% of the Italian female population, were included. Mixture cure models were used to estimate Net Survival (NS), Cure Fraction, Time To Cure (5-year conditional NS>95%), Cure Prevalence (women who will not die of cancer), and Already Cured (living longer than Time to Cure). In 2018, 0.4% (121,704) of Italian women were alive after corpus uteri cancer, 0.2% (52,551) after cervical, and 0.2% (52,153) after ovarian cancer. More than 90% of patients with uterine cancers and 83% with ovarian cancer will not die from their neoplasm (Cure Prevalence). Women with gynaecological cancers have a residual excess risk of death <5% after 5 years since diagnosis. The Cure Fraction was 69% for corpus uteri, 32% for ovarian, and 58% for cervical cancer patients. Time To Cure was ≤10 years for women with gynaecological cancers aged <55 years. 74% of patients with cervical cancer, 63% with corpus uteri cancer, and 55% with ovarian cancer were Already Cured. These results will contribute to improving follow-up programs for women with gynaecological cancers and supporting efforts against discrimination of already cured ones.